New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
10:27 EDTBCRX, NNVC, HEB, TKMRMapp drug used to treat Ebola patients, CNN reports
A drug made by privately held Mapp Biopharmaceutical was used to treat the two Americans who contracted Ebola, CNN reports, citing a source familiar with details of the treatment. The experimental treatment called ZMapp had never been tried before in a human but had showed promise with monkeys, CNN adds. Shares of Tekmira (TKMR), NanoViricides (NNVC), BioCryst (BCRX) and Hemispherx (HEB) are moving higher in early trading after two Americans were flown home with Ebola. Reference Link
News For TKMR;NNVC;BCRX;HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
06:00 EDTBCRXBioCryst upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
June 25, 2015
16:13 EDTHEBHemispherx files $77.9M mixed securities shelf
Subscribe for More Information
08:36 EDTHEBHemispherx receives notice of intention to grant patent from EU
Hemispherx announced that it received formal notice on June 18, that the European Patent Office's Examining Division issued the formal notification of intention to grant the Hemispherx application titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" by inventors Carter, et al. and assignee Hemispherx Biopharma, Inc. The patent claims a novel form of rugged dsRNA. Rugged dsRNA are nucleic acids with a unique composition and physical characteristic identified with high specificity of binding to Toll-Like Receptor 3, or TLR3, thereby conveying an important range of therapeutic opportunities. This form of dsRNA has increased bioactivity and binding affinity to the TLR 3 receptor because of its reduced tendency to form branched dsRNA that can inhibit receptor binding. Pharmaceutical formulations containing this nucleic acid as active ingredients, and methods of treatment with those formulations, are also described in the accepted application.
June 19, 2015
14:33 EDTTKMRTekmira main driver still hepatitis B program, says Leerink
Subscribe for More Information
09:18 EDTTKMROn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTTKMRTekmira provides update on TKM-Ebola-Guinea
Tekmira Pharmaceuticals announced that the Phase II clinical trial of TKM-Ebola-Guinea has reached a predefined statistical endpoint and enrollment has been closed. The endpoint indicated that continuing enrollment was not likely to demonstrate an overall therapeutic benefit. Data analysis is ongoing and the full results will be made available as soon as possible. In this trial, TKM-Ebola-Guinea is being evaluated for efficacy in Ebola virus infected patients in Sierra Leone, West Africa. The Phase II single arm trial called RAPIDE, or Rapid Assessment of Potential Interventions & Drugs for Ebola, is open-label with a concurrent observational study of Ebola virus disease in Sierra Leone.
June 17, 2015
06:54 EDTBCRXBioCryst licenses global rights for Rapivab influenza treatment to CSL
Subscribe for More Information
June 16, 2015
10:58 EDTBCRXBioCryst drug may have elicited severe immune thrombocytopenia, report says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use